Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Subpopulations of leukemic cells present at diagnosis can cause relapse in children with ALL

Scientists at St. Jude Children's Research Hospital and Princess Margaret Cancer Centre in Toronto, Canada, have reported that subpopulations of leukemic cells present at diagnosis can cause relapse in children with acute lymphoblastic leukemia.

3 Mar 2020

Treatments for rare diseases affecting children are increasing, study suggests

The number of treatments for rare diseases affecting children has increased, a new study suggests. But federal incentives intended to encourage drug development for rare conditions are being used more often to expand the use of existing drugs rather than for creating new ones.

3 Mar 2020

Harmful levels of metal linked to DNA damage found in the urine of e-cigarette users

Researchers at the University of California, Riverside, have completed a cross-sectional human study that compares biomarkers and metal concentrations in the urine of e-cigarette users, nonsmokers, and cigarette smokers.

20 Feb 2020

Universal 'One-Size-Fits-All' Cancer Treatment

Andrew Sewell speaks to News-Medical about his breakthrough research, in which he has discovered a new T-Cell that could treat most cancers.

14 Feb 2020

Death receptor pathway drives resistance to CAR T cell therapy

Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why.

30 Jan 2020

First randomized clinical trial compares targeted therapies for acute lymphoblastic leukemia

Researchers from St. Jude Children's Research Hospital and the Chinese Children's Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome.

17 Jan 2020

Research collaboration reveals potential treatment option for incurable blood cancers

Today, OncoTartis, Inc. and Children's Cancer Institute jointly announced the publication of two research manuscripts in a leading onco-hematological journal Leukemia, both devoted to the OncoTartis' clinical drug candidate OT-82.

16 Jan 2020

Leukemia patients treated with common cancer drug have heightened risk of heart failure

Patients with acute lymphoblastic leukemia or acute myeloid leukemia who are treated with anthracyclines are at a heightened risk of heart failure- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine.

17 Dec 2019

New therapy shows dramatic effect against worst types of leukaemias

A collaborative research effort by Australian and US scientists has led to the discovery of a promising new approach to treating some of the worst types of leukaemia, including an aggressive leukaemia that mostly affects babies.

11 Dec 2019

IONTAS antibody for the treatment of B-Cell ALL receives approval for clinical trials

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has been informed that International Biotechnology Center Generium, a leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia.

From FairJourney Biologics 11 Dec 2019

Immunotherapy more effective than chemotherapy for children, young adults with relapsed B-ALL

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed.

10 Dec 2019

Combination therapy is safe and effective for older patients diagnosed with acute lymphoblastic leukemia

A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (INO), with or without the drug blinatumomab, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL.

10 Dec 2019

New approach can improve the activity of CAR-T cells against blood and solid cancers

A new approach to programing cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiveness against human cancer cells grown in the laboratory and in mice, according to a study by researchers at the Stanford University School of Medicine.

5 Dec 2019

Scientists discover new approach to treating incurable leukemia in children

Acute lymphoblastic leukemia (ALL) is a form of blood cancer that primarily affects children and young people.

25 Nov 2019

Rutgers Cancer Institute researchers awarded $2.3 million in American Cancer Society grants

More than $2.3 million in Research Scholar Grants from the American Cancer Society have been awarded to three Rutgers Cancer Institute of New Jersey researchers to examine cell metabolism and tumor formation in forms of breast cancer, lung cancer and leukemia.

19 Nov 2019

Chemotherapy can cause drug-resistant mutations in pediatric ALL patients who relapse

Chemotherapy has helped make the most common childhood cancer one of the most curable, but researchers have evidence that the treatment may also prime some patients for relapse.

2 Nov 2019

TU Dresden scientists receive 4.5 million euros for fundamental research

Rapid growth of tumor tissue and metastasis formation are major problems of cancers. Cancer cells use a higher amount of energy than normal body cells and therefore undergo a metabolic reprogramming.

25 Oct 2019

Metabolite profiling during diagnosis helps identify poor treatment outcomes in ALL

The survival of patients with pediatric acute lymphoblastic leukemia (ALL) has significantly improved in the last several decades. However, novel strategies to identify cases that are likely to respond poorly to treatment are still needed.

24 Oct 2019

Reduced exercise capacity linked to neurocognitive problems in survivors of childhood ALL

A new study found a link between reduced exercise capacity and neurocognitive problems in survivors of acute lymphoblastic leukemia, the most common childhood cancer.

21 Oct 2019

Cytek Biosciences hits flow cytometry milestone: 40 color analysis from a single sample

Flow cytometry’s next chapter is here. Opening the door to deeper immunological insights, Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, today announced that it has successfully developed and demonstrated a high-quality 40-color panel from a single sample using the Cytek® Aurora advanced flow cytometry system.

From Cytek Biosciences 5 Oct 2019